2002/29/EC: Commission Decision of 8 January 2002 on financial assistance from the Community for storage in France, Italy and the United Kingdom of antigens for production of foot-and-mouth disease vaccines (notified under document number C(2001) 4736)
Data as of 2026-07-04 Β· Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. Β· Read the official text β
1. The Community shall grant financial assistance to France for the stocking of antigens for the production of foot-and-mouth disease vaccines. 2. The "Agence Française de Sécurité Sanitaire des Aliments (ASSA)" at Lyon in France shall hold the stock of antigens to which paragraph 1 relates. 3. The Community's financial assistance shall be up to a maximum of EUR 30000 for the period 1 January to 31 December 2002.
1. The Community shall grant financial assistance to Italy for the stocking of antigens for the production of foot-and-mouth disease vaccines. 2. The "Istituto Zooprofilattico Sperimentale Di Brescia" in Italy shall hold the stock of antigens to which paragraph 1 relates. 3. The Community's financial assistance shall be up to a maximum of EUR 30000 for the period 1 January to 31 December 2002.
1. The Community's financial assistance referred to in Article 1(3) and Article 2(3) shall be paid following the presentation by the Member State concerned of supporting documents which demonstrate the effective completion of the tasks. 2. The supporting documents referred to in paragraph 1 must be presented to the Commission before 1 March 2003 and they shall include: (a) technical information on: - the amount and type of antigen stored (storage records), - storage equipment used (type, number and capacity of tanks), - security systems in place (temperature control, anti-theft measures), - insurance arrangements (fire, accidents); (b) financial information (completion of table as shown in the Annex).
1. The Community shall grant financial assistance to Merial SAS, Lyon, France, for the stocking of antigens for the production of foot-and-mouth disease vaccines. 2. Merial SAS, Lyon, shall hold the stock of antigens to which paragraph 1 relates at the premises of Merial SAS in Lyon, France, (two containers) and at the premises of Pirbright, United Kingdom, (four containers). 3. The Community's financial assistance shall be up to a maximum of EUR 48000 for the period 1 January to 31 December 2002.
1. To meet the objectives of Article 4, the Commission shall conclude a contract with Merial SAS without delay. 2. The Director-General of the Directorate-General for Health and Consumer Protection shall be authorised to sign the contract on behalf of the European Commission.
This Decision is addressed to the Member States. Done at Brussels, 8 January 2002. For the Commission David Byrne Member of the Commission (1) OJ L 224, 18.8.1990, p. 19. (2) OJ L 203, 28.7.2001, p. 16. (3) OJ L 368, 31.12.1991, p. 21. (4) OJ L 66, 8.3.2001, p. 39. (5) OJ L 33, 8.2.2000, p. 19. (6) OJ L 160, 26.6.1999, p. 103.
>PIC FILE= "L_2002013EN.002702.TIF">
Source: EUR-Lex (Publications Office of the EU), Β© European Union, reuse permitted under Commission Decision 2011/833/EU.